rofecoxib has been researched along with Rheumatism in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Authors summarize the current knowledge on a new class of nonsteroidal anti-inflammatory drugs (NSAIDs), the coxib (celecoxib and rofecoxib), in the treatment of rheumatic diseases." | 4.81 | [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives]. ( Nervetti, A; Rioda, WT, 2001) |
| "To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis." | 3.73 | Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jaksch, W | 1 |
| Dejaco, C | 1 |
| Schirmer, M | 1 |
| Setakis, E | 1 |
| Leufkens, HG | 1 |
| van Staa, TP | 1 |
| Gibofsky, A | 1 |
| Bolten, WW | 1 |
| Reiter, S | 1 |
| Schneeweiss, S | 1 |
| Solomon, DH | 1 |
| Wang, PS | 1 |
| Rassen, J | 1 |
| Brookhart, MA | 1 |
| Suissa, S | 1 |
| Garbe, E | 1 |
| Gotlieb, D | 1 |
| Rioda, WT | 1 |
| Nervetti, A | 1 |
4 reviews available for rofecoxib and Rheumatism
| Article | Year |
|---|---|
4 years after withdrawal of rofecoxib: where do we stand today?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Contraindications; Cyclooxygenase | 2008 |
Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; La | 2002 |
Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages.
Topics: Antirheumatic Agents; Databases, Factual; Drug Therapy; Europe; Humans; Lactones; Medical Records; N | 2007 |
[Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2; Cyclooxygena | 2001 |
4 other studies available for rofecoxib and Rheumatism
| Article | Year |
|---|---|
Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Databases, Factual; D | 2008 |
[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Topics: Antirheumatic Agents; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase Inhibitors; D | 2005 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F | 2006 |
Celecoxib-- the debate ranges on.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Insurance Cover | 2001 |